Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

-- When compared to insulin glargine, exenatide offered added benefits of weight loss and improved beta-cell function when used with metformin --

AMSTERDAM, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced study results comparing treatment of exenatide injection with insulin glargine on beta-cell function, glycemic control and weight in people with type 2 diabetes. Study findings showed one year of exenatide therapy, as compared to insulin glargine, markedly improved different indices of beta-cell function, along with similar glycemic improvement. In addition, patients treated with exenatide lost weight, whereas patients treated with glargine gained weight. These findings were presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Amsterdam, The Netherlands(1).

In this randomized study, 69 people with type 2 diabetes who were treated with exenatide (5 mcg BID for 4 weeks and 10 mcg BID to 20 mcg TID (20 mcg TID is a currently unapproved dosage of the marketed formulation of exenatide, BYETTA(R) (exenatide) injection) for the remainder of the year) or insulin glargine (both with metformin) were compared on measures of beta-cell function, blood sugar control and weight change after one year (52-weeks) of treatment.

In this study, people with type 2 diabetes who used exenatide for one year, compared to those treated with i
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 2, 2015 ... market for global clinical trials review of H2, ... scenario with an objective to enhance decision making ... Complete report on Keratoconus market clinical trials ... companies, 10 institutes / government organizations and supported ...
(Date:9/1/2015)... Mass. , Sept. 1, 2015  Shareholder rights ... whether certain officers and directors of ConforMIS, Inc. (NASDAQGS: ... ConforMIS is a medical technology company that uses its ... joint replacement implants that are individually sized and shaped ... this press release on the law firm,s Shareholder Rights ...
(Date:9/1/2015)... , Sept. 1, 2015 On August 31, ... Jr. , issued a 123-page order in the first ... Medical Conserve metal-on-metal hip replacement devices are defective.[1]  ... judgment as to Plaintiff Robyn Christiansen,s claims for defective ... Court flatly rejected Wright Medical,s claim that the Medical ...
Breaking Medicine Technology:Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 3
... LONDON, April 21, 2012 Medaxial, the ... won a Queen,s Award for Enterprise in recognition of ... for Enterprise are the UK,s most prestigious business accolade, ... select number of companies who have achieved outstanding results ...
... INC. (Nasdaq: PDEX ) announced today that ... of Chief Executive Officer, effective immediately.  The Company also ... positions with the Company and its subsidiaries, including his ... a member of the Company,s Board of Directors, effective ...
Cached Medicine Technology:Pharmaceutical Industry Service Company Awarded The UK's Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade 2Pharmaceutical Industry Service Company Awarded The UK's Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade 3Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer 2Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer 3
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy , ... partnership with Apex Physical Therapy (Apex) is official as of August ... compassionate, and empathetic care to local residents from their combined eight locations throughout ...
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes in ... from everyday life changes can lead to very serious, life-altering events. Fortunately nature ... with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic doses of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... From Aug. 17-21, ... and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community ... 65 adult counselors, some of whom work for Calvary, and two junior counselors who ...
(Date:9/1/2015)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) has once again ... 50 Report that recognizes companies that provide the best career opportunities for Hispanic women ... number 24 to 21 of the 50 Best Companies for Latinas. The LATINA Style ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and prevent different malignancies. Some options for cancer treatment are available belonging ... which distinctive approach is necessary for effective treatment. Several molecules have been ...
Breaking Medicine News(10 mins):Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... Alzheimer,s disease that previously showed troubling side effects may ... The keys to the safety of the drug, ... it to patients with ApoE4, a gene mutation linked ...
... in the Fallopian tubes that carry eggs from a woman,s ... but this finding goes a long way towards explaining why ... pregnant," says Sean Ward, professor of physiology and cell biology, ... the study. Ward,s study was recently published ...
... A new drug targeting the PI3K gene in patients ... early phase I investigational study conducted at Virginia G. ... by oncologist Dr. Daniel D. Von Hoff at the ... Oncology (ASCO). The drug under investigation, GDC-0941, manufactured ...
... Beth Israel Deaconess Medical Center (BIDMC) has been awarded ... Infectious Diseases (NIAID), part of the National Institutes of ... in Nonhuman Primates. The five-year grant totals $36 million. ... MD, PhD, a Professor of Medicine at Harvard Medical ...
... WEDNESDAY, July 20 (HealthDay News) -- The meteorological monster -- ... throttled much of the United States from the Southwest to ... ushering in oppressive humidity, temperatures in the high 90s and ... wave, blamed for as many as 13 deaths in the ...
... with a serious genetic blood disorder are not getting the ... to sickness. Research funded by the Economic and ... of York and Loughborough University reveals that most children with ... in catching up on absences from class. Sickle ...
Cached Medicine News:Health News:Experimental Drug Might Help Fight Alzheimer's After All 2Health News:Experimental Drug Might Help Fight Alzheimer's After All 3Health News:Nevada School of Medicine researcher finds caffeine consumption, female infertility link 2Health News:TGen, Virginia G. Piper Cancer Center studying new breast cancer drug 2Health News:'Heat Dome' Continues to Throttle U.S. 2Health News:'Heat Dome' Continues to Throttle U.S. 3Health News:Schools failing pupils with sickle cell disease 2
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
PediaVision LLC is a life sciences company dedicated to solving the critical problem of undiagnosed vision problems affecting children worldwide....
... the treatment of presbyopia, a condition that affects ... patients. , Presbyopia results from the gradual loss ... eye as a person ages, making the lens ... eye has a harder time focusing on objects ...
Designed with your input, the ATS Simulus™ flexible annuloplasty ring and band are easy endings to complex mitral valve repairs....
Medicine Products: